PubMed Health⌕ Search

Biomedical subjects

B Timms

Publications and source records attributed to B Timms.

13 recordsLinked to original sources
PubMed1995

High frequency oscillatory ventilation: initial experience in 22 patients.

OBJECTIVES: To report the outcome of a consecutive cohort of neonates treated with high frequency oscillatory ventilation (HFOV). METHODOLOGY: Prospective cohort study of 22 neonates failing conventional mechanical ventilation (CMV) between October 1992 and August 1993. Outcomes evaluated were in-hospital survival rate, comorbidities including patent ductus arteriosus (PDA), cerebroventricular haemorrhages (CVH), necrotizing enterocolitis (NEC), bronchopulmonary dysplasia (BPD) and retinopathy of prematurity (ROP), and acute changes in respiratory status. RESULTS: Eighteen of 22 (81.8%) survived. Of the four children who died, one did not respond to HFOV and died within 24 h of treatment. Two died of respiratory failure complicated by pulmonary haemorrhage. The remaining infant responded to HFOV but later developed severe NEC while on minimal CMV and died at 2 weeks of age. Three subjects were > or = 34 weeks' gestation; each responded well to HFOV with no substantial comorbidity. Of the remaining 19 infants < 34 weeks' gestation, six (31.6%) had a PDA, and seven (36.8%) had a CVH. One infant developed cystic periventricular leucomalacia. Three infants (15.8%) had NEC. Respiratory failure in the 15 survivors with gestational ages < 34 weeks improved dramatically with HFOV. Ten (66.7%) survivors < 34 weeks developed BPD and 10 (66.7%) ROP. CONCLUSION: High frequency oscillatory ventilation was associated with a survival rate of 81.8%, but with significant comorbidity.

Barotrauma↗
PubMed1989

Comparative efficacy of terbutaline administered by Nebuhaler and by nebulizer in young children with acute asthma.

We compared the use of terbutaline sulphate that was delivered by a nebulizer with its delivery by a Nebuhaler at two dose levels in 27 children (nine children per group) of between three and six years of age with acute asthma. No significant difference was found in the mean baseline clinical score among the three groups, and a significant decline occurred in the mean clinical scores in all groups by 15 minutes which was maintained to 60 minutes after the dose was administered. The decline that was achieved with delivery of the drug by way of a Nebuhaler (at either dose level) was not significantly different from that with a nebulizer, although cooperation with Nebuhaler usage was not universal in the age-group.

Acute Disease↗